Overview

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
Phase:
Phase 4
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Pramipexole